The low price for Epizyme is due to their drug being approved only for relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation. A very narrow market. They do have a SETD2 inhibitor but it's in development. Their drugs are nothing like the widespread potential of leronlimab.